← Leaderboards
Stacey Lynn Clardy
Utah State Higher Education System--University Of Utah
$15,144,108
Attributed
$15,144,108
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,144,108 · 1
By mechanism
U01$15,144,108 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Accounting”
- Martha Hering · Westat, Inc.$57,098,843
- John Hobbs · Suny At Stony Brook$41,239,084
- Christopher Bee · Suny At Stony Brook$41,239,084
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Pamela Winer Goldberg · Medical Device Innovation Consortium$28,780,000
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
Research focus
AccountingAdmission ActivityAcuteAffectAntibodiesAntibody FormationAdverse EventAntibody Titer MeasurementAutoantibodiesAutoimmune EncephalitisB-Cell ActivationB Cell TherapyBehavioralBiologicalBiological MarkersAntibody TherapyBlast CellBloodBlood-Brain Barrier PenetrationB-LymphocytesBrainCase SeriesCd19 AntigensCd19 Gene
Grant awards (5)
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease$3,478,888
U01 · FY2025 · NS · contact PI
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease$50,489
U01 · FY2025 · NS · contact PI
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease$3,638,367
U01 · FY2024 · NS · contact PI
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease$3,970,523
U01 · FY2022 · NS · contact PI
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease$4,005,841
U01 · FY2021 · NS · contact PI